Matches in Wikidata for { <http://www.wikidata.org/entity/Q66392285> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q66392285 description "clinical trial" @default.
- Q66392285 description "ensayu clínicu" @default.
- Q66392285 description "klinisch onderzoek" @default.
- Q66392285 description "клінічне випробування" @default.
- Q66392285 name "Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen" @default.
- Q66392285 name "Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen" @default.
- Q66392285 type Item @default.
- Q66392285 label "Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen" @default.
- Q66392285 label "Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen" @default.
- Q66392285 prefLabel "Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen" @default.
- Q66392285 prefLabel "Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen" @default.
- Q66392285 P1050 Q66392285-5A8CE0BB-E802-4B8B-9C80-9C2BFFDF6818 @default.
- Q66392285 P1132 Q66392285-430D6698-50B5-4C34-AB34-D5B617EF3B7A @default.
- Q66392285 P1476 Q66392285-D9F5C9B5-FD06-4A0C-A03D-EA5A3B62EA82 @default.
- Q66392285 P17 Q66392285-E005BE31-0E51-4309-A6A5-C3547B97D300 @default.
- Q66392285 P1813 Q66392285-CD1ED199-4329-49AC-8B3B-AE431ACEC44F @default.
- Q66392285 P2899 Q66392285-B777B153-E6F9-4FAF-97F8-1EEC3A702FAD @default.
- Q66392285 P3098 Q66392285-8619EF05-6803-4C9F-89CE-512256F6F403 @default.
- Q66392285 P31 Q66392285-6AFF648F-5F3D-4007-B8C5-A6B392805566 @default.
- Q66392285 P580 Q66392285-C108D803-8B53-4BC9-B69D-786F2CD7103E @default.
- Q66392285 P582 Q66392285-FDA9806B-4C58-4C4B-9AC7-0D77D29B3363 @default.
- Q66392285 P6099 Q66392285-9BAECF1D-14BF-4398-A693-7CE26994CF04 @default.
- Q66392285 P767 Q66392285-88D83F57-4A11-447A-AFB0-C3097305918F @default.
- Q66392285 P8363 Q66392285-CE53FD75-88D4-40BC-A85B-4661E40FC2EA @default.
- Q66392285 P921 Q66392285-C29EFC94-2F6E-416A-946A-4C07FEBBE1E0 @default.
- Q66392285 P1050 Q33525 @default.
- Q66392285 P1132 "+450" @default.
- Q66392285 P1476 "A Phase II Safety Trial of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen" @default.
- Q66392285 P17 Q142 @default.
- Q66392285 P1813 "NIVOREN" @default.
- Q66392285 P2899 "+18" @default.
- Q66392285 P3098 "NCT03013335" @default.
- Q66392285 P31 Q30612 @default.
- Q66392285 P580 "2016-01-01T00:00:00Z" @default.
- Q66392285 P582 "2023-01-01T00:00:00Z" @default.
- Q66392285 P6099 Q42824440 @default.
- Q66392285 P767 Q266423 @default.
- Q66392285 P8363 Q78089383 @default.
- Q66392285 P921 Q7041828 @default.